TrialDiabetes care2010

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Steven E Kahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.